The present invention broadly relates to the improved method for purification of capsular polysaccharides. Particularly, the present invention relates to the method of purification of capsular polysaccharides from Streptococcus pneumoniae and other similar related capsular polysaccharides produced from both gram-negative and gram-positive microorganisms. More particularly, the invention involves passing the crude capsular polysaccharide solution through reinforced cellulose membrane having quaternary ammonium, and further contacting the solution with silicon dioxide (SiO2) and isolating the capsular polysaccharide in a pure form. The purified capsular polysaccharide is useful for producing vaccines that contain the polysaccharide alone or are conjugated to proteins.
The present invention relates to field of protein expression. It provides expression constructs and methods for increased expression of recombinant proteins. More particularly, it provides constructs and methods for enhanced expression of Lira-peptide in a recombinant host cell.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to conjugates comprising polysaccharides comprising 3- deoxy-D-manno-actulosonic acid (KDO) moieties, particularly conjugates produced using random conjugation methods, methods for preparing such conjugates, immunogenic compositions and vaccines comprising the conjugates, and methods of treatment or medical uses using the compositions and vaccines.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present disclosure relates to a process for preparing a stable floccule of paliperidone ester injectable suspension. The process comprises wet milling a premix slurry comprising paliperidone ester to obtain a milled suspension; and subjecting the milled suspension to heat treatment to produce a stable floccule of paliperidone palmitate injectable suspension; wherein the premix slurry is obtained by a single-phase manufacturing process that combines all the constituents of the slurry.
The present disclosure relates to compositions and methods for stabilizing immunogenic compositions. Particularly, the present disclosure provides an easy to prepare and economical stabilizer composition comprising components selected from a group comprising sugar(s), amino acid(s), protein(s) or peptide(s), mineral salt(s); and buffer(s) of any combination thereof. Further provided herein is a stabilized immunogenic composition comprising the stabilizer composition in combination with antigen(s) or pathogen(s) of interest? The present disclosure additionally provides methods for preparing the stabilizer composition and the stabilized immunogenic composition and applications thereof. The stabilizer composition of the present disclosure is easy to prepare and store. The stabilizer composition further confers long-term stability to immunogenic compositions, at various storage temperatures.
The present disclosure relates to expression cassettes that enhance protein secretion. The expression cassettes are composed of a specific combination of polynucleotides encoding expression enhancers and signal peptides that ensure a high yield of the protein of interest upon expression. Further provided herein are vector constructs and host cells characterized by the presence of the expression cassettes as referred to above and methods employing the same, for increased expression and secretion of biologically active peptides. Taken together, the present disclosure provides a cost-effective means of production of biologically active peptides.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 39/00 - Medicinal preparations containing antigens or antibodies
12.
ACTIVATED-QUENCHED POLYSACCHARIDE AND IMPROVED METHODS FOR QUANTIFICATION OF POLYSACCHARIDE IN A VACCINE COMPOSITION
The present invention provides a novel reference standard, comprising of activated-quenched polysaccharide, for quantifying polysaccharide content in a vaccine composition using nephelometry. The invention also provides a method for preparing the activated-quenched polysaccharide, for use as a reference standard. Further, a nephelometry based method for quantifying the polysaccharides in a multivalent conjugate vaccine is also provided. The reference standard of the present invention, comprising of the activated-quenched polysaccharide, is stable and can be used for accurate quantification of polysaccharides through nephelometry.
G01N 21/82 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
The present invention broadly relates to the improved method for purification of capsular polysaccharides. Particularly, the present invention relates to the method of purification of capsular polysaccharides from Streptococcus pneumoniae and other similar related capsular polysaccharides produced from both gram-negative and gram- positive microorganisms. More particularly, the invention involves passing the crude capsular polysaccharide solution through reinforced cellulose membrane having quaternary ammonium, and further contacting the solution with silicon dioxide (SiO2) and isolating the capsular polysaccharide in a pure form. The purified capsular polysaccharide is useful for producing vaccines that contain the polysaccharide alone or are conjugated to proteins.
The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also discloses vaccine compositions comprising the truncated peptides as carrier protein.
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C12N 15/77 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for CorynebacteriumVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Brevibacterium
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following: a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
The invention relates to an N-terminal extension sequences which are employed to enhance the expression of recombinant therapeutic peptides. The invention also relates to a process for the high-level expression of recombinant therapeutic peptides using the said N-terminal extension sequence. The invention also provides nucleic acids, vectors and recombinant host cells for efficient production of biologically active proteins such as lirapeptide.
C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
C12N 15/77 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for CorynebacteriumVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Brevibacterium
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
The present invention provides a colorimetric based method for quantifying carbohydrates in a given aqueous sample. The method provided by the invention uses 2-Phenoxyethanol as a novel reagent for quantifying carbohydrates in a given sample. The present invention is a rapid, sensitive, simple and direct method for carbohydrate quantification.
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
20.
CONSTRUCTS AND METHODS FOR INCREASED EXPRESSION OF POLYPEPTIDES
The present invention relates to field of protein expression. It provides expression constructs and methods for increased expression of recombinant proteins. More particularly, it provides constructs and methods for enhanced expression of Lira-peptide in a recombinant host cell.
The present invention relates to field of protein expression. It provides expression constructs and methods for increased expression of recombinant proteins. More particularly, it provides constructs and methods for enhanced expression of Lira-peptide in a recombinant host cell.
The present invention provides a novel reference standard, comprising of activated-quenched polysaccharide, for quantifying polysaccharide content in a vaccine composition using nephelometry. The invention also provides a method for preparing the activated-quenched polysaccharide, for use as a reference standard. Further, a nephelometry based method for quantifying the polysaccharides in a multivalent conjugate vaccine is also provided. The reference standard of the present invention, comprising of the activated-quenched polysaccharide, is stable and can be used for accurate quantification of polysaccharides through nephelometry.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to multivalent pneumococcal polysaccharide-protein conjugates vaccine composition comprising pneumococcal capsular polysaccharide of one or more Streptococcus pneumoniae serotypes conjugated to one or more carrier proteins.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to vaccine formulations comprising preservative systems. More particularly, the present invention relates to preservative systems for vaccine formulations which is free of thiomersal, and comprising 2-phenoxyethanol and at least one other preservative selected from m-cresol, benzyl alcohol, phenol and benzoic acid.
The present invention relates to Risperidone microspheres, process for preparing the microspheres, compositions comprising the Risperidone microspheres and their uses.
The present invention provides an improved process for the preparation of Enoxaparin sodium. The process is simple, commercially viable and industrially advantageous.
The present invention provides a colorimetric based method for quantifying carbohydrates in a given aqueous sample. The method provided by the invention uses 2-Phenoxyethanol as a novel reagent for quantifying carbohydrates in a given sample. The present invention is a rapid, sensitive, simple and direct method for carbohydrate quantification.
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
The present invention provides a colorimetric based method for quantifying carbohydrates in a given aqueous sample. The method provided by the invention uses 2-Phenoxyethanol as a novel reagent for quantifying carbohydrates in a given sample. The present invention is a rapid, sensitive, simple and direct method for carbohydrate quantification.
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
32.
N-TERMINAL EXTENSION SEQUENCE FOR EXPRESSION OF RECOMBINANT THERAPEUTIC PEPTIDES
The invention relates to an N-terminal extension sequences which are employed to enhance the expression of recombinant therapeutic peptides. The invention also relates to a process for the high-level expression of recombinant therapeutic peptides using the said N-terminal extension sequence. The invention also provides nucleic acids, vectors and recombinant host cells for efficient production of biologically active proteins such as lirapeptide.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
33.
N-TERMINAL EXTENSION SEQUENCE FOR EXPRESSION OF RECOMBINANT THERAPEUTIC PEPTIDES
The invention relates to an N-terminal extension sequences which are employed to enhance the expression of recombinant therapeutic peptides. The invention also relates to a process for the high-level expression of recombinant therapeutic peptides using the said N-terminal extension sequence. The invention also provides nucleic acids, vectors and recombinant host cells for efficient production of biologically active proteins such as lirapeptide.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The present invention provides an improved process for the preparation of Dalteparin sodium. The process is simple, commercially viable and industrially advantageous.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
35.
Method for separation of protein and other impurities from microbial capsular polysaccharides
The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also discloses vaccine compositions comprising the truncated peptides as carrier protein.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C12N 15/77 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for CorynebacteriumVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Brevibacterium
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention pertains to a multivalent vaccine formulation comprising at least one inactivated poliovirus (IPV) S19 strain selected from S19 Type 1, S19 Type 2 and S19 Type 3 and at least one antigen selected from Diphtheria toxoid (DT), Tetanus toxoid (TT), whole-cell Bordetella pertussis (wP), acellular Pertussis (aP), Hepatitis B surface protein, Haemophilus influenzae Type b polysaccharide, Inactivated Japanese encephalitis (JE) virus and Inactivated Rotavirus 116E strain (IRV). The multivalent vaccine formulation of the present invention provide protection against several diseases, simplify vaccine administration and improve vaccine compliance.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
The present invention relates to multivalent pneumococcal polysaccharide-protein conjugates vaccine composition comprising pneumococcal capsular polysaccharide of one or more Streptococcus pneumoniae serotypes conjugated to one or more carrier proteins.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides inactivated poliomyelitis vaccine compositions comprising at least one inactivated poliovirus S19 strain for prevention of poliomyelitis. The present invention provides safe, stable and effective vaccine formulations which can be manufactured at low containment level leading to large scale production of poliomyelitis vaccines.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
45.
VACCINE FORMULATIONS COMPRISING PRESERVATIVE SYSTEM
The present invention relates to vaccine formulations comprising preservative systems. More particularly, the present invention relates to preservative systems for vaccine formulations which is free of thiomersal, and comprising 2-phenoxyethanol and at least one other preservative selected from m-cresol, benzyl alcohol, phenol and benzoic acid.
The present invention relates to novel semi-synthetic meningococcal conjugate vaccine comprising novel synthetic oligosaccharide conjugated to a carrier protein. The present invention also relates to novel synthetic meningococcal oligosaccharide and a process for its preparation.
The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also discloses vaccine compositions comprising the truncated peptides as carrier protein.
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
48.
IMPROVED PROCESS FOR THE PREPARATION OF DALTEPARIN SODIUM
The present invention provides an improved process for the preparation of Dalteparin sodium. The process is simple, commercially viable and industrially advantageous.
The present invention provides an improved process for the preparation of Dalteparin sodium. The process is simple, commercially viable and industrially advantageous.
197, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the said precipitate and finally obtaining the Aluminum phosphate gel.
The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
The present invention provides an improved process for the preparation of Enoxaparin sodium. The process is simple, commercially viable and industrially advantageous.
The present invention provides an improved process for the preparation of Enoxaparin sodium. The process is simple, commercially viable and industrially advantageous.
C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
55.
Industrially scalable process for recovering biologically active recombinant carrier proteins
Escherichia coli and purification thereof. More particular, the invention relates to industrially scalable process for the recovery of recombinant carrier proteins.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
C07K 1/12 - General processes for the preparation of peptides by hydrolysis
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
56.
AN IMPROVED METHOD FOR HIGH LEVEL PRODUCTION OF CRM197
The present invention provides an improved method for the production of CRM197 with high yield using engineered Corynebacterium diphtheria strain having increased copy number of CRM197 gene, wherein the method comprises growing the strain in a media free of animal derived components with one or more amino acids.
The present invention provides an improved method for the production of CRM197 with high yield using engineered Corynebacterium diphtheria strain having increased copy number of CRM197 gene, wherein the method comprises growing the strain in a media free of animal derived components with one or more amino acids.
The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
The present invention relates to a preparation method which is performed by expressing the recombinant carrier proteins in Escherichia coli and purification thereof. More particular, the invention relates toindustrially scalable process for the recovery of recombinant carrier proteins.
The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: 1) at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F of S. pneumoniae activated with CDAP and conjugated to carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.
The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: 1) at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F of S. pneumoniae activated with CDAP and conjugated to carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.
The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the said precipitate and finally obtaining the Aluminum phosphate gel.
The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the said precipitate and finally obtaining the Aluminum phosphate gel.
The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
The present invention relates to a soft-gelatin capsule formulation of antitussive agents. More particularly, the present invention relates to soft-gelatin capsule formulation comprising Noscapine or its pharmaceutically acceptable salts alone or in combination with one or more therapeutically active agents.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
70.
CODON OPTIMIZED POLYNUCLEOTIDE FOR HIGH LEVEL EXPRESSION OF CRM197
The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRM197 wherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. More particularly, the present invention relates to high level expression of CRM197 in Escherichia coli and a method for the isolation and purification thereof.
The present invention relates to novel semi-synthetic meningococcal conjugate vaccine comprising novel synthetic oligosaccharide conjugated to a carrier protein. The present invention also relates to novel synthetic meningococcal oligosaccharide and a process for its preparation.
AN IMPROVED PROCESS FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES OF HAEMOPHILUS INFLUENZA - B, NEISSERIA MENINGITIS SUCH AS SEROTYPES A, C, Y AND W-135, AND OTHER SIMILAR RELATED CAPSULAR POLYSACCHARIDES PRODUCED FROM BOTH GRAM NEGATIVE AND GRAM POSITIVE MICROORGANISMS USING ALUMINIUM PHOSPHATE WITH ALCOHOL.
A manufacturing process for preparing pure capsular polysacharide using aluminum phosphate with alcohol for the purification of capsular polysaccharides of Haemophilus influenza - b, Neisseria meningitidis such as serotypes A, C, Y, W- 135 and other similar related capsular polysaccharides produced form both gram negative and gram positive microorganisms is described. The process is applicable, simple, robust and easily scalable. The purified polysaccharide can be used in the preparation of covalent conjugates comprising the polysaccharide linked to a carrier protein. Purified polysaccharides meet all the specifications required by WHO and can be used as a vaccine component for both polysaccharide and conjugate vaccines.
